Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Histone Deacetylase (HDAC) Inhibitors Market’s Growth Rate Evolve Over the Forecast Period to 2034?

In the past few years, the market for histone deacetylase (HDAC) inhibitors has expanded significantly. The market is predicted to escalate from $1.23 billion in 2024 to $1.33 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. The upward trend during the historical period can be linked to an increase in funding for epigenetic research, an uptick in cases of drug-resistant cancers, increased healthcare spending, amplified use of HDAC inhibitors in veterinary medicine, and a rise in investment in bioinformatics.

In the coming years, a robust rise is projected in the histone deacetylase (HDAC) inhibitors market. The market is anticipated to expand to $1.77 billion by 2029, with a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this increase during the forecast period include an escalation in cases of neurodegenerative disorders, heightened awareness of cancer, boosted spending on drug development, a rising number of clinical trials, and a surge in the embracing of personalized medicine. Key trends for the forecast period encompass technological progression, personalized medicine, synergies in cancer immunotherapy, the merging of digital health solutions, and bioinformatics.

What Combination of Drivers Is Leading to Accelerated Growth in the Histone Deacetylase (HDAC) Inhibitors Market?

The escalating occurrence of neurodegenerative diseases is projected to boost the expansion of the histone deacetylase (HDAC) inhibitors market in the future. These disorders, marked by gradual decay and eventual neuron death in the brain and spinal cord, lead to cognitive and motor impairments, encompassing illnesses like Alzheimer’s, characterized by memory deterioration and cognitive degradation due to amyloid accumulations and tau clusters. The augmenting prevalence of neurodegenerative diseases can be credited to multiple aspects like age, lifespan, genetics, and environmental triggers. Histone deacetylase (HDAC) inhibitors are under investigation as potential remedies for neurodegenerative diseases due to their capability to alter gene expression and offer neuroprotective impacts. For example, in August 2024, the Centers for Disease Control and Prevention, a federal agency from the United States, reported an estimated 6.7 million elderly adults in the country are living with Alzheimer’s disease, a figure projected to surge to nearly 14 million by 2060. Hence, the escalating prevalence of neurodegenerative diseases is facilitating the expansion of the histone deacetylase (HDAC) inhibitors market.

Get Your Free Sample of the Global Histone Deacetylase (HDAC) Inhibitors Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp

Who Are the Influential Players Reshaping the Histone Deacetylase (HDAC) Inhibitors Market Landscape?

Major companies operating in the histone deacetylase (HDAC) inhibitors market are:

• Bristol-Myers Squibb Company_x000D_

• Novartis AG_x000D_

• Merck KGaA_x000D_

• Abcam plc_x000D_

• Pharmacyclics LLC_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Histone Deacetylase (HDAC) Inhibitors Market?

Leading organizations in the histone deacetylase (HDAC) inhibitors market are concentrating on devising innovative approaches, like HDAC inhibitors for cancer therapy, as a way to increase effectiveness and minimize side effects. HDAC inhibitors are a category of drug compounds utilized in cancer treatments, which work by limiting the action of HDAC enzymes that usually detach acetyl units from histone proteins. This restriction results in heightened acetylation of histones, modifying chromatin structure and impacting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., an American company, which is known for developing innovative cancer therapies, received new HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These innovative inhibitors are designed to target particular HDAC enzymes involved in the advancement of cancer, with the goal of obstructing abnormal gene expression patterns contributing to tumor expansion and metastasis. The patented compounds showcase improved potency and selectivity, thereby diminishing the chances of off-target impacts and enhancing safety standards for patients undergoing treatment.

Get Instant Access to the Global Histone Deacetylase (HDAC) Inhibitors Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report

How Are the Key Segments of the Histone Deacetylase (HDAC) Inhibitors Market Impacting Its Expansion and Revenue Streams?

The histone deacetylase (HDAC) inhibitors market covered in this report is segmented –

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs

2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors

3) By Application: Oncology, Neurology, Other Applications

4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments

1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8

2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10

3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7

4) By Class IV HDACs: HDAC11

Which Geographic Locations Are Critical to the Growth of the Histone Deacetylase (HDAC) Inhibitors Market?

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Histone Deacetylase (HDAC) Inhibitors Market?

Histone deacetylase (HDAC) inhibitors refer to a class of compounds that block the activity of histone deacetylase enzymes. These enzymes are responsible for removing acetyl groups from histone proteins, which leads to a more condensed chromatin structure and reduced gene expression. HDAC inhibitors can promote hyperacetylation of histones, which generally leads to a more relaxed chromatin structure and increased accessibility of DNA for transcription factors.

Browse Through More Similar Reports By The Business Research Company:

Interleukin Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report

ACE Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Checkpoint Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: